Companies › Propedix
1 active drug program in 3 registered trials: 3 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 1% Tolnaftate Stick Formula A Antifungal inhibitor of squalene epoxidase | – | Phase 2 | Tinea Pedis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07245667 | 1% Tolnaftate Stick Formula A | Phase 2 | Tinea Pedis | Infectious disease | Feb 2026 |
| NCT07245667 | 1% Tolnaftate Stick Formula A | Phase 2 | Tinea Pedis | Infectious disease | Feb 2026 |
| NCT07245667 | 1% Tolnaftate Stick Formula A | Phase 2 | Tinea Pedis | Infectious disease | Feb 2026 |
No annotated target.
–
Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma Peptilogics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.